Cargando…

Effects of Monotherapy with Clopidogrel vs. Aspirin on Vascular Function and Hemostatic Measurements in Patients with Coronary Artery Disease: The Prospective, Crossover I-LOVE-MONO Trial

Objectives: To evaluate the effect of clopidogrel vs. aspirin monotherapy on vascular function and hemostatic measurement. Background: Monotherapy with P2Y(12) receptor inhibitor vs. aspirin can be a useful alterative to optimize clinical efficacy and safety in high-risk patients with coronary arter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Hyun-Woong, Kang, Min-Gyu, Ahn, Jong-Hwa, Bae, Jae-Seok, Tantry, Udaya S., Gurbel, Paul A., Jeong, Young-Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235752/ https://www.ncbi.nlm.nih.gov/pubmed/34202960 http://dx.doi.org/10.3390/jcm10122720

Ejemplares similares

Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases
por: Gurbel, Paul A, et al.
Publicado: (2010)

Further evidence for the use of aspirin in COVID-19
por: Tantry, Udaya S., et al.
Publicado: (2022)

Cost-Effectiveness of Clopidogrel vs Aspirin Monotherapy After Percutaneous Coronary Intervention: Results From the HOST-EXAM Study
por: Hwang, Doyeon, et al.
Publicado: (2023)

Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome
por: Kang, Min Gyu, et al.
Publicado: (2022)

Comparative effect of clopidogrel plus aspirin and aspirin monotherapy on hematological parameters using propensity score matching
por: Hayasaka, Masatoshi, et al.
Publicado: (2013)

IS LOW DOSE ASPIRIN EFFECTIVE IN REDUCING IN-HOSPITAL CLINICAL OUTCOMES IN PATIENTS WITH COVID-19?
por: Gurbel, Paul A., et al.
Publicado: (2021)

Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis
por: Paciaroni, Maurizio, et al.
Publicado: (2019)

Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention
por: Jeong, Young-Hoon, et al.
Publicado: (2012)

In Vitro Evidence for the Role of Cytokine Storm in the Generation of Stent Thrombosis in COVID-19 Patients
por: Gurbel, Paul A., et al.
Publicado: (2022)

Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery
por: Qu, Jianyu, et al.
Publicado: (2021)

Aspirin and Clopidogrel Resistance
por: Sztriha, Laszlo K., et al.
Publicado: (2004)

Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent
por: Tantry, Udaya S, et al.
Publicado: (2021)

Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus
por: Jung, Jung Hwa, et al.
Publicado: (2015)

Personalized antiplatelet therapy: state of the art
por: Gurbel, Paul A, et al.
Publicado: (2012)

Temporal Variability of Platelet Reactivity Phenotype: Another Barrier to Personalized Antiplatelet Strategy Guided by Platelet Function Testing
por: Jeong, Young-Hoon, et al.
Publicado: (2019)

International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests
por: Gurbel, Paul A., et al.
Publicado: (2021)

Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population
por: Gurbel, Paul A., et al.
Publicado: (2021)

Effects of Cilostazol on Platelet Activation in Coronary Stenting Patients Who Already Treated with Aspirin and Clopidogrel.
por: Ahn, Jeong Cheon, et al.
Publicado: (2004)

State of the art: Oral antiplatelet therapy
por: Gurbel, Paul A, et al.
Publicado: (2016)

High-Dose, but Not Low-Dose, Aspirin Impairs Anticontractile Effect of Ticagrelor following ADP Stimulation in Rat Tail Artery Smooth Muscle Cells
por: Grześk, Grzegorz, et al.
Publicado: (2013)

Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis
por: Yuan, Jun, et al.
Publicado: (2019)

Efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention in patients with coronary artery disease: a meta-analysis
por: Liu, Di, et al.
Publicado: (2023)

Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV: A Randomized Controlled Trial
por: Marcantoni, Emanuela, et al.
Publicado: (2022)

Aspirin vs Clopidogrel: Antiplatelet Agent of Choice for Those With Recent Bleeding or at Risk for Gastrointestinal Bleed
por: Gosavi, Siddharth, et al.
Publicado: (2023)

Aspirin and clopidogrel resistance: methodological challenges and opportunities
por: Gasparyan, Armen Yuri
Publicado: (2010)

Aspirin/clopidogrel: Lack of efficacy: case report
Publicado: (2020)

Another Unmet Need against Residual Risk of Atherosclerotic Cardiovascular Disease: Can “Thrombin Pathway” Be a New Target for Therapy?
por: Kim, Hyun Kuk, et al.
Publicado: (2020)

IS THERE A ROLE FOR α1-ANTITRYPSIN IN COVID-19?
por: Gurbel, Paul A., et al.
Publicado: (2021)

AGE-BASED RISK FACTORS FOR SYMPTOMATIC COVID-19 IN THE MINORITY POPULATION
por: Gurbel, Paul A., et al.
Publicado: (2021)

Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis
por: Tan, Shuai, et al.
Publicado: (2015)

Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
por: Neubauer, Horst, et al.
Publicado: (2011)

Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis
por: Yao, Jia-Chen, et al.
Publicado: (2018)

Is clopidogrel superior to aspirin in secondary prevention of vascular disease?
por: Algra, Ale, et al.
Publicado: (2000)

Mapping the antiplatelet effects of clopidogrel and aspirin by modified thromboelastography
por: Hemlata,, et al.
Publicado: (2013)

Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences
por: Kim, Hyun Kuk, et al.
Publicado: (2021)

Association Between Thrombogenicity Indices and Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction
por: Kang, Min Gyu, et al.
Publicado: (2021)

Comparison of Triple Anti-Platelet Therapy (Aspirin, Clopidogrel, and Cilostazol) and Double Anti-Platelet Therapy (Aspirin and Clopidogrel) on Platelet Aggregation in Type 2 Diabetic Patients Undergoing Drug-Eluting Stent Implantation
por: Yang, Tae-Hyun, et al.
Publicado: (2009)

Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting
por: Sharma, Rakesh K, et al.
Publicado: (2009)

Comparison of Midterm Outcomes Associated With Aspirin and Ticagrelor vs Aspirin Monotherapy After Coronary Artery Bypass Grafting for Acute Coronary Syndrome
por: Björklund, Erik, et al.
Publicado: (2021)

Residual Inflammatory Risk and its Association With Events in East Asian Patients After Coronary Intervention
por: Ahn, Jong-Hwa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_64hpchorr3qdia37tlu6h3nona